Edaravone (Radicava ORS)

Small molecule

Also known as MT-1186

Approvedregulatory verdict

Evidence outlook

Approved: Amyotrophic Lateral Sclerosis

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Weak signal

Also approved (2)
KR
  • ALS (Radicut oral suspension, edaravone)
Product first approved 2025thepharmaletter.com
JP
  • ALS (Radicut Oral Suspension 2.1%, edaravone)
Product first approved 2022medthority.com

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (6)
Amyotrophic Lateral Sclerosis
NCT00415519 · Shionogi
2006-12-31 – 2008-07-31 · Amyotrophic Lateral Sclerosis (ALS)
What this study did
Other / comorbidity
NCT04569084 · Shionogi
2020-11-13 – 2023-09-29 · ALS
What this study did
NCT05151471 · Shionogi
2022-01-11 – 2023-09-29 · ALS
What this study did
NCT05568615 · Shionogi
2022-10-26 – 2023-06-27 · ALS
What this study did
NCT04165824 · Shionogi
2019-11-18 – 2021-10-07 · ALS
What this study did
Phase 1 (10)
Amyotrophic Lateral Sclerosis
NCT04254913 · Shionogi
2020-01-24 – 2020-04-22 · Japanese Patients With ALS
What this study did
NCT04176224 · Shionogi
2019-04-17 – 2019-09-04 · Japanese Patients With ALS
What this study did
Other / comorbidity
NCT06107205 · Shanghai Auzone Biological Technology Co., Ltd.
2023-11-07 – 2023-12-14 · Healthy Adult Subjects
What this study did
NCT04776135 · Shionogi
2021-02-26 – 2021-04-16 · Healthy Adult Subjects
What this study did
NCT05342597 · Shionogi
2019-06-10 – 2019-07-24 · Healthy Adult Subjects
What this study did
NCT04493281 · Shionogi
2019-03-22 – 2019-05-09 · Healthy Adult Subjects
What this study did
NCT03664544 · Shionogi
2018-11-06 – 2019-03-25 · Severe Hepatic Impairment, Healthy
What this study did
NCT04481789 · Shionogi
2018-10-17 – 2019-01-08 · Healthy Adult Subjects
What this study did
NCT04481750 · Shionogi
2018-03-20 – 2018-08-03 · Healthy Adult Subjects
What this study did
NCT03289208 · Shionogi
2016-10-27 – 2018-04-20 · Renal Impairment, Healthy
What this study did
Phase 4 (1)
Other / comorbidity
NCT00200356 · Shionogi
2004-08-31 – 2006-10-31 · Cerebral Infarction
What this study did

Competitive landscape

This drug's own stage for Amyotrophic Lateral Sclerosis: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Edaravone (Radicava ORS): this drugApprovedSmall moleculeReactive oxygen species (ROS)Weak signalFeatured results are safety only in this race
Tofersen (Qalsody)ApprovedRNA / oligonucleotideSOD1Partial signalNo reviewed efficacy summary in this indication
MasitinibPhase 3Small moleculeKIT (c-Kit), also PDGFR and Lyn/Fyn kinasesnot yet gradedNo reviewed efficacy summary in this indication
UlefnersenPhase 3RNA / oligonucleotideFUSReliable signal
NCT04768972: FUSION (NCT04768972): ulefnersen met its primary endpoint, a joint rank (win-ratio style) analysis of time to death/permanent ventilation, time to rescue, and change in ALSFRS-R score to Day 505 vs placebo; p=0.0005.
CB03-154Phase 2/3Small moleculeKCNQ2/3 (Kv7.2/7.3) potassium channel (opener)not yet gradedNo reviewed efficacy summary in this indication
CNM-Au8Phase 2/3Nanoparticlemitochondrial energy metabolismnot yet gradedNo reviewed efficacy summary in this indication
IbudilastPhase 2/3Small moleculePDE4 and PDE10; macrophage migration inhibitory factor (MIF)not yet gradedNo reviewed efficacy summary in this indication
Tazbentetol (SPG302)Phase 2/3Small moleculeDendritic spine densityWeak signalFeatured results are safety only in this race
DazucorilantPhase 2Small moleculeGlucocorticoid receptornot yet gradedNo reviewed efficacy summary in this indication
ForalumabPhase 2Monoclonal antibodyCD3not yet gradedNo reviewed efficacy summary in this indication
ALN-SODPhase 1/2RNA / oligonucleotideSOD1not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.